07.14.25 -- June 2025 — CDMO Opportunities And Threats Report

Review how the EMA supports rare disease drug development through regulatory and financial incentives for therapies that meet strict eligibility and ongoing compliance criteria.

Enhance the success of your research and cell therapy programs by sourcing PBMCs with proven functional performance and donor-specific insights.

Discover how a company is overcoming purification challenges and advancing scalable, GMP-ready LVV manufacturing for gene and cell therapies.

Clinical Trials Day celebrates the science and collaboration driving medical breakthroughs — discover how Cryoport Systems helps power this progress behind the scenes.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Ensure a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Learn about the development and effective scale-up of a robust process for manufacturing adenovirus vectors and the obstacles that were encountered and successfully overcome.

As advanced therapies race forward, staying ahead is paramount. Harnessing technology, sponsors can unlock efficiencies and propel AAV production to new heights.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.